

PRESS RELEASE

Enzymicals AG acts on international markets: Intellectual Property Rights for recombinant isoforms of pig liver esterases (PLE) granted in Japan

Greifswald 28th of May 2014 – following 11 western European countries, China and U.S. the intellectual property rights for isoforms of pig liver esterases were granted in Japan for Enzymicals AG. This is an important step for the SME, which is based in Greifswald, Germany. Enzymicals is a supplier of tailor-made biocatalysts as well as a developer of biocatalytic processes for the production of fine and specialty chemicals.

PLEs are widely used in organic synthesis especially for the regio- and enatioselective hydrolysis, e.g. for the cleavage of chiral carboxylic acid ester for the preparation of secondary and tertiary alcohols, or the cleavage of lactones. So far in industry, extracts from animal tissues are used. The advantage of the recombinant production of the Isoenzymes lies in non-animal origin, the purity of the enzymes and in the batch to batch reproducibility. Thus a constant quality of catalyst is assured. The PLE isoenzymes are available worldwide through the catalogue business of Enzymicals and Sigma Aldrich. In cooperation with its network partners, it is possible to deliver industrially relevant quantities of the individual isoforms.

The basis for these now granted patents were laid through a cooperation of the working group of Prof. U. Bornscheuer, one of the founding fathers of Enzymicals, with Evonik Industries AG.

About Enzymicals AG:

Enzymicals has a highly recognized expertise in enzymatic processes for the synthesis of sophisticated compounds. We design and develop cost effective and sustainable chemical and biochemical routes for the production of APIs and fine chemicals, which can be transferred to

Contact:

Enzymicals AG Dr. Ulf Menyes CEO Walther-Rathenau-Str. 49a 17489 Greifswald, Germany

Tel.: +49-3834-515 470 Fax.: +49-3834-515 473 E-Mail: info@enzymicals.com www.enzymicals.com

Enzymicals AG 1



industrial scales. We provide enzymes suitable for research and production of high-quality substances. Our service includes the route scouting for the synthesis of compounds desired by our customers, up to feasibility studies and final applications orientated on customer demands. Together with our partners BRAIN AG and the BBG "Braun Beteiligungs GmbH", to which also the company Herbrandt Pharma-Chemicals belongs, Enzymicals is integrated in a strategic network, which covers the whole value chain from identification and improvement of biocatalysts, process development and optimization up to commercial production under GMP conditions, distribution and regulatory issues.

For more information: www.enzymicals.com



Enzymicals AG 2